| Ubrelvy (ubrogepant) / AbbVie |
ACHIEVE I, NCT02828020: Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine |
|
|
| Completed | 3 | 1672 | US | Ubrogepant, Placebo-matching Ubrogepant | Allergan | Migraine, With or Without Aura | 12/17 | 12/17 | | |
|
| Completed | 3 | 1686 | US | Ubrogepant, Placebo-matching Ubrogepant | Allergan | Migraine, With or Without Aura | 01/18 | 02/18 | | |
|
NCT02873221: An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine |
|
|
| Completed | 3 | 1254 | US | Ubrogepant, Placebo-matching Ubrogepant, Usual Care | Allergan | Migraine, With or Without Aura | 08/18 | 08/18 | | |
PRODROME, NCT04492020: Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants |
|
|
| Completed | 3 | 518 | US | Ubrogepant 100 mg, Placebo | AbbVie | Migraine | 04/22 | 04/22 | | |
UBRO MM, NCT06417775: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine |
|
|
| Recruiting | 3 | 496 | US | Ubrogepant, UBRELVY, Placebo for Ubrogepant | AbbVie | Migraine | 06/27 | 09/27 | | |
NCT05125302: Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) |
|
|
| Recruiting | 3 | 1059 | US | Ubrogepant, Ubrelvy, Placebo-Matching Ubrogepant | AbbVie | Migraine | 05/26 | 05/26 | | |
NCT05127954: Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) |
|
|
| Enrolling by invitation | 3 | 1200 | US | Ubrogepant, Ubrelvy | AbbVie | Migraine | 01/28 | 01/28 | | |
